| Biomarker ID | 693 |
| PMID | 21788966 |
| Year | 2011 |
| Biomarker | Triplex Model (TRPM8 + MSMB+AMACR) |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Urine |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: [TRPM8: 1.130 (95% CI: 1.040–1.229), P=0.004]; OR: [MSMB: 0.761 (95% CI: 0.620–0.933), P= 0.009] |
| Effect on Pathways | Pathways include (AMACR):- Primary bile acid biosynthesis, Bile acids and bile salt biosynthesis, Peroxisomal lipid metabolism, Bile acid and bile salt biosynthesis via 7-alpha-hydroxycholesterol, Bile acid and bile salt metabolism Pathways Include(TRPM8):-Ion channel transport; Development Endothelin-1/EDNRA signaling;CREB Pathway; Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds;TRP channels Pathways Include(MSMB):-Oncostatin M |
| Experiment | Prostate Cancer Vs Non- Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | Total of 176 people were included in the study. A subset with PSA in range (3–15 ng/ml) were selcted out of which 62 had prostate Cancer and 24 did not have Prostate Cancer. |
| Senstivity | 77.4% |
| Specificity | 61.8% |
| AUC | 0.726 (95% CI: 0.617–0.836) |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | qPCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | TRPM8, MSMB, AMACR |